Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report

EGFR-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment for NSCLC. However, acquired drug resistance often occurs after treatment with EGFR-TKIs. EGFR T790M and C797S mutations are the most common resistance mechanism in patients who failed from first- and third- generation EGFR TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuanyang, Chen, Yuxing, Huang, Huaying, Li, Xi, Shao, Lin, Ding, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114361/
https://www.ncbi.nlm.nih.gov/pubmed/33994798
http://dx.doi.org/10.2147/OTT.S300556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114361/
https://www.ncbi.nlm.nih.gov/pubmed/33994798
http://dx.doi.org/10.2147/OTT.S300556

Ejemplares similares